BioNTech Expands Management Board by Appointing James Ryan as Chief
Legal Officer
MAINZ, Germany, August 14, 2023 –
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced
that the Supervisory Board has appointed James Ryan, Ph.D., to the
Management Board as Chief Legal Officer (CLO), effective September
1, 2023. As part of the Management Board, James Ryan will continue
to lead the Company’s corporate legal strategy and global legal
operations including transactions, corporate governance,
securities, intellectual property (IP), insurance, data privacy,
among others. Prior to his appointment to the Management Board,
James Ryan served as the Company’s General Counsel and Senior Vice
President Legal & IP.
“We are looking forward to welcoming James Ryan
to the Management Board. Since joining BioNTech in 2018, he has
been a trusted advisor and a proven senior leader, given his
extensive global experience across key healthcare legal and
compliance domains,” said Helmut Jeggle, Chairman of the
BioNTech Supervisory Board. “James Ryan has played a pivotal
role in BioNTech’s development from a private business into a
globally integrated biopharmaceutical company. He combines
scientific and legal expertise in an extraordinary manner,
contributing to BioNTech’s continued success and growth trajectory.
We also value James for his contributions to strengthen BioNTech’s
unique culture and his commitment to continue to do so in the
future.”
“BioNTech is entering a decisive phase in the
Company’s transformation. As our pipeline candidates move into
later stages of clinical development, we are working towards trials
with registrational potential and focus on building commercial
capabilities for potential market launches,” said James Ryan,
Senior Vice President Legal & IP and Chief Legal
Officer-designate at BioNTech. “I believe BioNTech has a unique
opportunity to contribute to improving the health of people
worldwide and I am looking forward to help accomplish this crucial
mission as part of the Management Board.”
James Ryan has nearly 20 years of global legal
and IP expertise in the pharmaceutical industry. He joined BioNTech
in July 2018. Since then, he has guided the Company through a wide
range of key business, IP and transactional activities, equity
capital markets transactions including the Company’s IPO in 2019,
mergers and acquisitions, and strategic collaborations. He and his
teams played a pivotal role in the successful development of the
Pfizer-BioNTech COVID-19 Vaccine, supporting every aspect of the
program, its launch and commercialization.
James Ryan has a Ph.D. in epigenetics from the
University of St Andrews, is a member of the Law Society of England
& Wales and is a member of the Law Society of Ireland.
Supporting material: Photos of Helmut Jeggle and
James Ryan, Ph.D. can be found in BioNTech’s newsroom.
About BioNTechBiopharmaceutical New
Technologies (BioNTech) is a next generation immunotherapy company
pioneering novel therapies for cancer and other serious diseases.
The Company exploits a wide array of computational discovery and
therapeutic drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor (CAR) T cells,
several protein-based therapeutics, including bispecific immune
checkpoint modulators, targeted cancer antibodies and antibody-drug
conjugate (ADC) therapeutics, as well as small molecules. Based on
its deep expertise in mRNA vaccine development and in-house
manufacturing capabilities, BioNTech and its collaborators are
developing multiple mRNA vaccine candidates for a range of
infectious diseases alongside its diverse oncology pipeline.
BioNTech has established a broad set of relationships with multiple
global pharmaceutical collaborators, including DualityBio, Fosun
Pharma, Genentech, a member of the Roche Group, Genevant, Genmab,
OncoC4, Regeneron, Sanofi, and Pfizer.
For more information, please visit
www.BioNTech.com.
BioNTech Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including, but not be limited to, statements
concerning: the potential benefits of BioNTech’s leadership hires;
BioNTech’s research and development programs, including statements
regarding studies or trials with registrational potential and
related preparatory work and the availability of results; and
BioNTech’s focus on building commercial capabilities for potential
market launches. In some cases, forward-looking statements can be
identified by terminology such as “will,” “may,” “should,”
“expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential,” “continue,” or the negative
of these terms or other comparable terminology, although not all
forward-looking statements contain these words. The forward-looking
statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors, many of which are beyond
BioNTech’s control and which could cause actual results to differ
materially from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to: discussions with regulatory agencies regarding timing
and requirements for additional clinical trials; the ability to
produce comparable clinical results in future clinical trials;
competition related to BioNTech’s product candidates, including
those with different mechanisms of action and different
manufacturing and distribution constraints, on the basis of, among
other things, efficacy, cost, convenience of storage and
distribution, breadth of approved use, side-effect profile and
durability of immune response; the timing of and BioNTech’s ability
to obtain and maintain regulatory approval for BioNTech's product
candidates; BioNTech’s and its counterparties’ ability to manage
and source necessary resources; BioNTech’s ability to identify
research opportunities and discover and develop investigational
medicines; the ability and willingness of BioNTech's third-party
collaborators to continue research and development activities
relating to BioNTech's development candidates and investigational
medicines; BioNTech’s and its collaborators’ ability to
commercialize and market its product candidates, if approved;
BioNTech's ability to manage its development and expansion;
regulatory developments in the United States and other countries;
BioNTech’s ability to effectively scale BioNTech’s production
capabilities and manufacture BioNTech’s product candidates; and
other factors not known to BioNTech at this time.
You should review the risks and uncertainties
described under the heading “Risk Factors” in BioNTech’s Report on
Form 6-K for the period ended June 30, 2023 and in subsequent
filings made by BioNTech with the U.S. Securities and Exchange
Commission (“SEC”), , which are available on the SEC’s website at
www.sec.gov. Except as required by law, BioNTech disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release in the
event of new information, future developments or otherwise. These
forward-looking statements are based on BioNTech’s current
expectations and speak only as of the date hereof.
CONTACTS
BioNTechMedia RelationsJasmina
Alatovic+49 (0)6131 9084 1513Media@biontech.de
Investor RelationsVictoria Meissner, M.D.+1 617
528 8293Investors@biontech.de
Grafico Azioni Biontech (LSE:0A3M)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Biontech (LSE:0A3M)
Storico
Da Mag 2023 a Mag 2024